학술논문
Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study
Document Type
Article
Author
Source
In International Immunopharmacology December 2023 125 Part B
Subject
Language
ISSN
1567-5769